×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TXMD – therapeuticsmd, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TXMD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
03:06 am
txmd
TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/15
06:59 am
txmd
TherapeuticsMD Third Quarter 2024 Earnings: US$0.049 loss per share (vs US$0.13 loss in 3Q 2023) [Yahoo! Finance]
Medium
Report
TherapeuticsMD Third Quarter 2024 Earnings: US$0.049 loss per share (vs US$0.13 loss in 3Q 2023) [Yahoo! Finance]
11/15
03:07 am
txmd
TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/12
04:05 pm
txmd
TherapeuticsMD Announces Third Quarter 2024 Financial Results
Low
Report
TherapeuticsMD Announces Third Quarter 2024 Financial Results
11/9
02:07 am
txmd
TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/3
02:07 am
txmd
TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
10/28
02:03 am
txmd
TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
10/22
02:02 am
txmd
TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
04:40 pm
txmd
Form SC 13G TherapeuticsMD, Inc. Filed by: Clearline Capital LP
Medium
Report
Form SC 13G TherapeuticsMD, Inc. Filed by: Clearline Capital LP
11/12
04:18 pm
txmd
Form 10-Q TherapeuticsMD, Inc. For: Sep 30
Medium
Report
Form 10-Q TherapeuticsMD, Inc. For: Sep 30
11/12
04:16 pm
txmd
Form 8-K TherapeuticsMD, Inc. For: Nov 12
Low
Report
Form 8-K TherapeuticsMD, Inc. For: Nov 12
10/25
05:03 pm
txmd
Form ARS TherapeuticsMD, Inc. For: Dec 31
Neutral
Report
Form ARS TherapeuticsMD, Inc. For: Dec 31
10/25
05:02 pm
txmd
Form DEFA14A TherapeuticsMD, Inc.
Neutral
Report
Form DEFA14A TherapeuticsMD, Inc.
10/25
05:01 pm
txmd
Form DEF 14A TherapeuticsMD, Inc. For: Dec 05
Neutral
Report
Form DEF 14A TherapeuticsMD, Inc. For: Dec 05
9/20
05:01 pm
txmd
Form 8-K TherapeuticsMD, Inc. For: Sep 20
Low
Report
Form 8-K TherapeuticsMD, Inc. For: Sep 20
8/26
05:40 pm
txmd
Form 4 TherapeuticsMD, Inc. For: Aug 22 Filed by: Collins Cooper C.
Low
Report
Form 4 TherapeuticsMD, Inc. For: Aug 22 Filed by: Collins Cooper C.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/29
Form 10-K/A TherapeuticsMD, Inc. For: Dec 31
76.0%
3/24 TherapeuticsMD Strengthens Board with Appointment of Industry Leaders 21.6%
8/6 Q2/2019 6/30/2019 EPS -0.230 ZacksConsensus -0.170 ActVsEst (0.060) - Miss 20.9%
1/21 Form SC 13G/A TherapeuticsMD, Inc. Filed by: JPMORGAN CHASE & CO 20.6%
9/25 Form 8-K TherapeuticsMD, Inc. For: Sep 25 13.4%
2/5 TherapeuticsMD Inc (NASDAQ: TXMD) had its "buy" rating re-affirmed by analysts at Noble Financial. They now have a $13.00 price target on the stock. 11.7%
8/14 Form 4 TherapeuticsMD, Inc. For: Aug 12 Filed by: Milligan John C.K. IV 9.6%
12/23 TherapeuticsMD Inc (NASDAQ: TXMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock. 8.2%
9/16 Form 8-K TherapeuticsMD, Inc. For: Sep 16 7.9%
2/11 TherapeuticsMD: Inside The Numbers [Seeking Alpha] 6.6%
3/24 TherapeuticsMD Strengthens Board with Appointment of Industry Leaders 21.6%
8/6 Q2/2019 6/30/2019 EPS -0.230 ZacksConsensus -0.170 ActVsEst (0.060) - Miss 20.9%
1/21 Form SC 13G/A TherapeuticsMD, Inc. Filed by: JPMORGAN CHASE & CO 20.6%
9/25 Form 8-K TherapeuticsMD, Inc. For: Sep 25 13.4%
2/5 TherapeuticsMD Inc (NASDAQ: TXMD) had its "buy" rating re-affirmed by analysts at Noble Financial. They now have a $13.00 price target on the stock. 11.7%
8/14 Form 4 TherapeuticsMD, Inc. For: Aug 12 Filed by: Milligan John C.K. IV 9.6%
12/23 TherapeuticsMD Inc (NASDAQ: TXMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock. 8.2%
9/16 Form 8-K TherapeuticsMD, Inc. For: Sep 16 7.9%
2/11 TherapeuticsMD: Inside The Numbers [Seeking Alpha] 6.6%
TOP News Decliners
10/23
TherapeuticsMD Announces Estimated Third Quarter 2019 Financial Results
-21.6%
6/11 TherapeuticsMD Inc (NASDAQ: TXMD) had its "outperform" rating re-affirmed by analysts at Cowen Inc. They now have a $9.00 price target on the stock, down previously from $16.00. -20.9%
4/30 TherapeuticsMD Inc (NASDAQ: TXMD) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -19.4%
5/6 Q1/2019 3/31/2019 EPS -0.160 ZacksConsensus -0.170 ActVsEst 0.010 - Beat -18.1%
3/26 TherapeuticsMD Provides COVID-19-Related Business Update -16.9%
3/16 TherapeuticsMD Provides Business Update on COVID-19 Pandemic -12.5%
8/13 Form 4 TherapeuticsMD, Inc. For: Aug 09 Filed by: Thompson Tommy G -11.9%
2/20 Q4/2019 12/31/2019 EPS -0.190 ZacksConsensus -0.200 ActVsEst 0.010 - Beat -11.2%
8/10 TherapeuticsMD Inc (NASDAQ: TXMD) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -8.6%
12/2 TherapeuticsMD Inc (NASDAQ: TXMD) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. -8.3%
6/11 TherapeuticsMD Inc (NASDAQ: TXMD) had its "outperform" rating re-affirmed by analysts at Cowen Inc. They now have a $9.00 price target on the stock, down previously from $16.00. -20.9%
4/30 TherapeuticsMD Inc (NASDAQ: TXMD) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -19.4%
5/6 Q1/2019 3/31/2019 EPS -0.160 ZacksConsensus -0.170 ActVsEst 0.010 - Beat -18.1%
3/26 TherapeuticsMD Provides COVID-19-Related Business Update -16.9%
3/16 TherapeuticsMD Provides Business Update on COVID-19 Pandemic -12.5%
8/13 Form 4 TherapeuticsMD, Inc. For: Aug 09 Filed by: Thompson Tommy G -11.9%
2/20 Q4/2019 12/31/2019 EPS -0.190 ZacksConsensus -0.200 ActVsEst 0.010 - Beat -11.2%
8/10 TherapeuticsMD Inc (NASDAQ: TXMD) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -8.6%
12/2 TherapeuticsMD Inc (NASDAQ: TXMD) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. -8.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: